Information Provided By:
Fly News Breaks for September 22, 2017
MYGN
Sep 22, 2017 | 07:36 EDT
Stephens analyst Drew Jones said that after the firm hosted a series of panels with healthcare industry professionals, he believes Myriad Genetics is well positioned to benefit from two key themes that came to the forefront - limiting risk and reducing cost. Jones, who noted that genetic testing was cited repeatedly as a potential lever for cost savings, reiterates his Overweight rating on Myriad and raised his price target on the stock to $40 from $36.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.